2021 McDonald Fellowships and Du Pré Grant recipients announced

MSIF is proud to announce the recipients of the 2021 McDonald Fellowships and Du Pré Grants, from Argentina, Brazil, Egypt, Iran, and Tunisia

Global webcast on fatigue in progressive MS

Register below for the global webcast on fatigue research and treatment

Progressive MS Alliance – MS stories from across the world

Find out about the lives of seven people affected by progressive MS.

Professor Alan Thompson wins the prestigious MS Charcot Award

Professor Thompson wins the 2021 lifetime achievement award for outstanding research into the understanding and treatment of MS

Alliance funds 19 Research Challenge Awards looking for answers on progression

In time for World MS Day, €1,425,000 has been awarded to help identify new therapeutic targets in progressive MS

Answering questions on progressive MS treatment and research

Watch the International Progressive MS Alliance webcast

Clinical research and trials

Research and clinical trials are taking place around the world, trying to find and improve treatments for MS

Catch up on the latest breakthroughs in progressive MS treatments

A first-of-its-kind global research network funded by the International Progressive MS Alliance aims to develop new, effective treatments for progressive MS.

Progressive MS research

The International Progressive MS Alliance works to speed up the development of treatment for progressive MS

Progressive MS and accelerating breakthough treatments

Global webcast on 4 March

Research on fighting MS brain inflammation with information from the gut

This paper was first published in Nature January 2021

2020 McDonald Fellowships and Du Pré Grant recipients announced

MSIF is proud to announce the recipients of the 2020 McDonald Fellowships and Du Pré Grants, from Iran, Zambia, Brazil, Turkey, and Argentina

Join the discussion on symptom management & well-being in progressive MS

Register for the Progressive MS Alliance's Facebook Live event

Primary progressive MS risk may be linked to genes that cause other brain diseases 

Genetic screening of people with primary progressive MS has shown that four rare genetic changes, which are known to cause other neurological diseases, may play a role in primary progressive MS.

A potential biomarker for progressive MS

The use of neurofilament light chain (NfL) as a biomarker could revolutionise clinical trials in progressive MS.

How do we accelerate life-changing treatments for people with progressive MS?

Join the discussion about research breakthroughs that could accelerate new treatments for people with progressive MS

Super-charging mitochondria – a potential pathway to treat progressive MS

New research funded by the International Progressive MS Alliance looks at ways that nerve fibres protect themselves from damage.

Answering today’s big questions in progressive MS

Watch the International Progressive MS Alliance webcast here

Discovering life-changing treatments for progressive MS

An International Progressive MS Alliance global webcast

Cervical cord damage and disability in MS

Cord lesion load and spinal cord atrophy may contribute to disability in people with progressive MS

First treatment for people with secondary progressive MS in Europe is approved

An important milestone for people with secondary progressive MS in Europe

Let’s talk about symptoms and well-being in progressive MS

Register for the Progressive MS Alliance's Facebook Live event on symptom management and well-being in progressive MS

Challenges in Progressive MS Awards: taking risks to reap rewards

Progressive MS Awards

Key topics in MS research

Thousands of scientists are undertaking research into all aspects of MS, furthering our understanding of the disease and how to prevent, treat and manage it.

First MS organisation in Latin America joins the Progressive MS Alliance

The International Progressive MS Alliance is growing!

Global webcast on solving progressive MS: progress achieved and hope for the future

Results released from first multi-drug clinical trial in MS

The results of the MS-SMART trial, an innovative trial testing multiple drugs at the same time, have ruled out three repurposed drugs for the treatment of progressive MS.

Asthma medication could slow brain atrophy in progressive MS

A phase II clinical trial has shown ibudilast, a repurposed asthma medication, can slow down the rate of brain tissue loss in progressive MS by almost half compared to a placebo treatment.

Making a difference through rehab research at the Progressive MS Alliance Conference

Researchers, clinicians and people living with MS, from around the world converged on the city of Toronto in Canada for the 3rd Congress of the International Progressive MS Alliance.

The winding path of MS progression

How the biological processes cause progression in different types of MS.

Siponimod offers hope for people with secondary progressive MS

A new, international clinical trial has shown that siponimod can slow progression in people with secondary progressive MS.

Antidepressant drug may treat Progressive MS

Screening of almost 250 medications has identified clomipramine as a possible treatment for progressive MS.

First treatment for early primary progressive MS approved in Europe

The European Commission has approved the first disease-modifying therapy, ocrelizumab, for early primary progressive MS (PPMS).

European Medicines Agency recommends market authorisation for ocrelizumab (Ocrevus) in EU

The EMA has recommended that ocrelizumab (Ocrevus), the first disease-modifying treatment for primary progressive MS (PPMS), be prescribed for adults with early primary progressive MS

First treatment licensed for primary progressive MS in the US

Ocrelizumab has been approved as a treatment for both relapsing and primary progressive MS in the US

Neurobiology and immunology

Neurobiology and immunology are key areas of MS research

What happened at ECTRIMS 2016?

Researchers and health professionals gather for the latest updates and research findings on treatment, care and management of MS

People affected by MS helping to steer research in progressive MS

Video from Caroline Sincock who recently joined the International Progressive MS Alliance

What happened at ECTRIMS 2015?

Our highlights from the world’s largest scientific conference on multiple sclerosis

Second Scientific Congress of the International Progressive MS Alliance

Challenges and next steps considered

Progressive MS webinar transcript

Full text of our 2014 webinar with experts on progressive MS

Intrathecal Rituximab is not effective in progressive multiple sclerosis

A recent study has failed to show any benefit for Rituximab in people with secondary progressive MS

Fingolimod is not effective in primary progressive multiple sclerosis

A new trial has failed to show Fingolimod has any effect of in primary-progressive MS

Results from a long-term observational study on MS

Long-term follow-up studies could help determine predictive factors for long-term clinical outcomes

New target for understanding secondary progressive MS

Chemical in the brain involved in signaling may play a role in progressive MS

Giancarlo Comi wins Charcot Award

The Charcot Award recognises a lifetime of achievement in MS research

International Progressive MS Alliance funds global research collaboration

Collaborative Network Planning Awards Granted as part of €22 million global effort to End Progressive MS

Highlights from the ‘Living with MS Day’

On 6 October, 650 people affected by MS gathered in Barcelona for the ‘Living with MS Day’ event

Positive results for people with primary progressive MS

The results from a phase III clinical trial of Ocrelizumab in primary progressive MS are announced at ECTRIMS

Delaying the development of secondary progressive MS

Recovery from early relapses can potentially delay or prevent onset of progressive MS

Characteristics of primary progressive MS

Researchers in Canada have investigated the natural history of 500 people with primary progressive MS

Biomarkers of inflammation in progressive MS

There is a need to identify direct biomarkers of inflammation within the central nervous system

A non-invasive method to identify MS progression

Researchers are looking for new biomarkers of disease, which could also recognise progression of MS in a reasonable time

Spinal cord is affected early in primary progressive MS

Study suggests that early spinal neurodegeneration may underlie clinical impairment

Progressive MS Alliance seeks lay members for Scientific Steering Committee

Three people needed to help shape the work of the Alliance

Changes in thalamus as a measure of progression in MS

Study supports a link between the development of grey matter disease and a progressive MS phenotype

New biomarkers to predict progression in MS

Neurofilaments are a good way to monitor nerve damage and treatments in progressive MS

Disease-modifying drugs may reduce disability progression in relapsing-remitting MS

Researchers found a lower risk of disability progression at the 10-year follow-up in the RRMS group compared with historical cohorts

Progressive MS Alliance expands

The Alliance has been joined by four MS International Federation member organisations

Progressive MS and disease-modifying drugs

Patients with secondary progressive MS who have ongoing relapses may benefit from continuing immunomodulatory therapies after onset of progressive MS

Disappointing results from fingolimod trial in primary progressive MS

The results suggest that primary progressive and relapsing forms of MS have different underlying mechanisms

Alliance announces first round of grants

The Progressive MS Alliance has awarded its first round of 22 research grants to investigators in nine countries

Types of MS

There are four main types of MS: clinically isolated syndrome, relapsing MS, secondary progressive MS and primary progressive MS.